Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Apr;124(9):1524-1532.
doi: 10.1038/s41416-020-01164-1. Epub 2021 Feb 18.

Survival from breast cancer in women with a BRCA2 mutation by treatment

D Gareth Evans  1 , Kelly-Anne Phillips  2   3   4 , Roger L Milne  4   5   6 , Robert Fruscio  7 , Cezary Cybulski  8 , Jacek Gronwald  8 , Jan Lubinski  8 , Tomasz Huzarski  8   9 , Zerin Hyder  1 , Claire Forde  1 , Kelly Metcalfe  10 , Leigha Senter  11 , Jeffrey Weitzel  12 , Nadine Tung  13 , Dana Zakalik  14 , Maria Ekholm  15 , Ping Sun  10 , Steven A Narod  16   17 ; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group
Collaborators, Affiliations
Multicenter Study

Survival from breast cancer in women with a BRCA2 mutation by treatment

D Gareth Evans et al. Br J Cancer. 2021 Apr.

Erratum in

  • Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment.
    Evans DG, Phillips KA, Milne RL, Fruscio R, Cybulski C, Gronwald J, Lubinski J, Huzarski T, Hyder Z, Forde C, Metcalfe K, Senter L, Weitzel J, Tung N, Zakalik D, Ekholm M, Sun P, Narod SA; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group. Evans DG, et al. Br J Cancer. 2023 Feb;128(4):703. doi: 10.1038/s41416-022-02130-9. Br J Cancer. 2023. PMID: 36639528 Free PMC article. No abstract available.

Abstract

Background: The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation.

Methods: We identified 664 women with stage I-III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective). Subjects were followed for 7.2 years from diagnosis to death from breast cancer. Tumour characteristics and cancer treatments were patient-reported and derived from medical records. Predictors of survival were determined using Cox proportional hazard models, adjusted for other treatments and for prognostic features.

Results: The 10-year breast-cancer survival for ER-positive patients was 78.9% and for ER-negative patients was 82.3% (adjusted HR = 1.23 (95% CI, 0.62-2.45, p = 0.55)). The 10-year breast-cancer survival for women who had a bilateral oophorectomy was 89.1% and for women who did not have an oophorectomy was 59.0% (adjusted HR = 0.45; 95% CI, 0.28-0.72, p = 0.001). The adjusted hazard ratio for chemotherapy was 0.83 (95% CI, 0.65-1.53: p = 0.56).

Conclusions: For women with breast cancer and a germline BRCA2 mutation, positive ER status does not predict superior survival. Oophorectomy is associated with a reduced risk of death from breast cancer and should be considered in the treatment plan.

PubMed Disclaimer

Conflict of interest statement

Steven A. Narod is a board member of BJC. All other authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1. Ten-year breast cancer-specific survival for women with BRCA2 mutations.
a ER-positive versus ER-negative. b Grade 1/2 versus Grade 3. c Endocrine therapy versus no endocrine therapy.
Fig. 2
Fig. 2. Ten-year breast cancer-specific survival for women with BRCA2 mutations.
a Oophorectomy versus no oophorectomy (all subjects). b Oophorectomy versus no oophorectomy (subjects in matched analysis only).
See this image and copyright information in PMC

References

    1. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 2010;28:375–379. doi: 10.1200/JCO.2008.20.7019. - DOI - PubMed
    1. Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Res. Treat. 2018;168:513–521. doi: 10.1007/s10549-017-4605-x. - DOI - PubMed
    1. Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015;1:306–313. doi: 10.1001/jamaoncol.2015.0658. - DOI - PubMed
    1. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226. doi: 10.1136/bmj.g226. - DOI - PMC - PubMed
    1. Jayasekara H, MacInnis RJ, Chamberlain JA, Dite GS, Leoce NM, Dowty JG, et al. Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis. Int. J. Cancer. 2019;145:3207–3217. doi: 10.1002/ijc.32214. - DOI - PMC - PubMed

Publication types

MeSH terms